RxDoctor Payments Data

Marina Kravets, MD

Internal Medicine · Langhorne, PANPI 1528018736

Payments from drug & device makers

$2,354in general payments, 2019–2025

Across 142 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$255
  • Lilly USA, LLC$229
  • AstraZeneca$223
  • Novartis$163
  • Boehringer Ingelheim$162
  • Novo Nordisk$147
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,31698%
  • Other$382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,354 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$151,375
Medicare patients
307
Services billed
1,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate68$75,898
JardianceEmpagliflozin47$62,343
ProliaDenosumab33$57,360
EliquisApixaban42$41,939
MounjaroTirzepatide28$28,137
OzempicSemaglutide28$28,044
FarxigaDapagliflozin Propanediol28$23,700
XareltoRivaroxaban24$14,002
LinzessLinaclotide21$11,449
Levothyroxine Sodium371$6,261
Novolog FlexpenInsulin Aspart14$5,930
Atorvastatin Calcium419$5,166
Ezetimibe111$5,041
Tegretol XrCarbamazepine12$5,021
SynthroidLevothyroxine Sodium47$4,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$162$62,34347 claims
AmgenProlia$75$57,36033 claims
PfizerEliquis$255$41,93942 claims
Lilly USA, LLCMounjaro$229$28,13728 claims
Novo NordiskOzempic$147$28,04428 claims
AstraZenecaFarxiga$223$23,70028 claims
AbbVieLinzess, Synthroid$72$15,73468 claims
Johnson & JohnsonXarelto$106$14,00224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →